Concurrent chemoradiotherapy using paclitaxel plus cisplatin in the treatment of elderly patients with esophageal cancer

Objective: This study aimed at assessing the efficiency and safety of concurrent chemoradiotherapy (CCRT) using paclitaxel (PTX) plus cisplatin (CDDP) in elderly (age ≥70 years) esophageal cancer patients.

Patients and methods: Between July 2008 and June 2011, 82 esophageal cancer patients aged ≥70 years were retrospectively analyzed. Chemotherapy consisted of CDDP for 3 days plus PTX given for 3 hours. The preplanned total dose of concurrent irradiation with 60 Gy/30 Fx was given at the 1st day of chemotherapy.

Results: The average age for the enrolled patients was 76.41 years (range: 70–87 years), and the clinical stages were stage I (two patients), stage II (23 patients), stage III (49 patients), and stage IV (eight patients). A total of 66 patients finished CCRT on schedule, including 55 (67.1%) patients in whom treatment regimen was not changed, and the clinical complete response was achieved in 29 patients. With a median follow-up time of 20.4 months, the median overall survival (OS) time and progression-free survival (PFS) time were 26.9 months and 18.2 months, respectively. The 2-year OS and PFS rates for stage I–II and III–IV were 76.0%, 64.0% and 38.6%, 21.2%, respectively. Grade 3 leukopenia was observed in 25 patients, and the most common nonhematologic toxicity was esophagitis including five and two patients with grade 3 and 4, respectively. Multivariate analysis revealed that clinical stage was a strong factor for OS and PFS.

Conclusion: CCRT using PTX plus CDDP for selected elderly esophageal cancer patients resulted in encouraging survival outcomes and tolerable toxicities. Future prospective studies in large cohorts are highly warranted to confirm the findings in our report.

Keywords: esophageal cancer, elderly, concurrent chemoradiotherapy, paclitaxel, survival, toxicity

Introduction
Esophageal cancer remains one of the most fatal cancers worldwide (representing 7% of all gastrointestinal cancers internationally). The overall 5-year survival rate for all patients with esophageal cancer is no better than a mere 20%, and it is estimated that over 20% of patients with esophageal cancer are diagnosed at an elderly age. Traditionally, esophagectomy plays the pivotal role for the treatment of early-stage and localized esophageal cancer, but it is less frequently performed in elderly patients. A series of reports had revealed that postoperative mortality rates in patients aged ≥70 years ranged from 4.5% to 23% and may even reach 60%. Concurrent chemoradiotherapy (CCRT) has also been considered as the standard treatment option for patients with inoperable or unresectable diseases, for which elderly patients account for a great proportion as established by the landmark results of Radiation Therapy Oncology Group (RTOG) 8501. A combination of fluorouracil (5-FU) and cisplatin (CDDP) has also been confirmed as a standard
radiotherapy.

However, the efficacy of this regimen was only approximately 25%–35%, and the median survival time was no better than 16 months in advanced esophageal cancer patients.7,8 Thus, exploring other potent radiosensitizers and more effective and tolerable anticancer drugs in elderly patients is gaining momentum.

Paclitaxel (PTX), a broad-spectrum cytotoxic drug, is a promising agent against esophageal cancer. Preclinical studies had shown that PTX can enhance radiation sensitivity of tumor cells, potentiate tumor response, and increase the therapeutic ratio of radiotherapy.9 Clinical trials had also revealed that substituting PTX for 5-FU and combining with CDDP had achieved better efficacy in a neoadjuvant and definitive setting for advanced esophageal cancer, and the effective rate was approximately 50%–60% with a more favorable toxicity profile,10–12 which was also validated in our cancer center.13 But, to our knowledge, no specific data have been published regarding the regimes of PTX and CDDP (TP regime) combined with radiotherapy in the setting of CCRT for elderly esophageal cancer patients.

Based on this background, we performed a retrospective study to investigate the feasibility and efficiency of CCRT with PTX and CDDP for elderly esophageal cancer patients treated in our cancer center. We defined an elderly population as persons aged ≥70 years, according to a series of recent studies.13–16

Patients and methods
Patients work-up
Between July 2008 and June 2011, 248 consecutive patients with newly diagnosed esophageal cancer underwent CCRT at the cancer center of Wenzhou Medical University. Of these patients, 82 (33.1%) patients aged over 70 years were retrospectively reviewed. This study was approved by the Institutional Review Boards of Wenzhou Medical University, and patients’ records were anonymized and deidentified prior to analysis. The main reasons for indication of CCRT and/or contraindication of surgery were rejection of surgery (n=19) or no indication of surgery because of advanced age (n=16), lower Eastern Cooperative Oncology Group (ECOG) performance status (PS) (n=18), severe comorbidity (n=14), or tumor location (cervical esophagus) (n=15).

Criteria for inclusion in our study included 1) histological diagnosis of esophageal cancer; 2) clinical stages I–IV disease according to the International Union Against Cancer (UICC, 2002) TNM stage criteria; 3) ECOG PS of at least 2; 4) no evidence of severe organ dysfunction; 5) adequate bone marrow, renal, hepatic, cardiac, and respiratory function (white blood cell >3,000/μL, platelet counts >10×10⁹/μL, serum creatinine <1.5 mg/dL); and 6) no prior chest radiation or chemotherapy received. Patient’s baseline characteristics (dysphagia, weight loss, albumin, hemoglobin, comorbidities) were also collected. Degree of dysphagia was evaluated using the Atkinson score,17 and the Charlson score was adopted for the analysis of patient’s comorbidities, which was based on 19 medical conditions.18

Treatment schedule and dose modification
PTX (135 mg/m²) was administered intravenously over 3 hours on day 1 and day 29 with standard premedications. CDDP (30 mg/m²) was administered as an intravenous infusion on days 1–3 and days 29–31. Radiotherapy was given concurrently on the 1st day of the first cycle of chemotherapy (Figure 1). The gross tumor volume (GTV) received 60 Gy (30 fractions at 2 Gy per fraction) and clinical target volume (CTV) was 40 Gy (20 fractions at 2 Gy per fraction). Radiotherapy was delivered in three-dimensional conformal technique, and no intensity-modulated radiotherapy was used. The definition of GTV, CTV, and dose-volume constraints of normal tissue in our institute has been described previously.13,19

Chemotherapy was delayed for acute toxicities until recovery to grade ≤1, and/or the dose was reduced for grade 3 or higher hematological toxicity. PTX was reduced to 80% in the second course if any of the following occurred: grade 3 neutropenia with fever or grade 4 neutropenia. Granulocyte colony-stimulating factor (G-CSF) was used to treat for the occurrence of febrile neutropenia. If the creatinine clearance decreased to less than 50 mL/min, the CDDP dose was also reduced to 80%. Irradiation was interrupted for grade ≥3 esophagitis, grade 3 neutropenia with fever, or grade 4 neutropenia. Radiation therapy was restarted when toxicities recovered to grade ≤2.

Evaluation and follow-up
All the patients were hospitalized and monitored weekly during the treatment course for acute treatment toxicity.
Physician-reported hematological, esophageal, and pulmonary toxicities were evaluated according to the common toxicity criteria for adverse events version 3.0. Clinical response was assessed according to Response Evaluation Criteria in Solid Tumors system 4 weeks after the completion of treatment, and follow-up was regularly carried out at 3-month interval in the first 2 years and at 6-month interval after 2 years. Treatment failure was defined as any sign of recurrent disease, which could be local, distant, or both. And, we also assessed failure models by posttreatment esophagogram, endoscopy, computed tomography (CT), or integrated positron emission tomography/CT (if available) scans and compared those data with the original CT-based radiation treatment plans.

Statistical analysis
All the statistical analyses were performed using SPSS version 16.0 software (SPSS Inc., Chicago, IL, USA). Overall survival (OS) was determined as the time (in months) between the 1st day of therapy and the last follow-up or the date of death. Progression-free survival (PFS) was calculated from the date of CCRT initiation to the date of documented failure (local recurrence or metastasis occurrence) or the date of the last follow-up for those still alive. Survival curves were determined using the Kaplan–Meier method. Given that a small portion of our raw data (<5%) was considered as missing data, we imputed these missing data with mean substitution. Predictive factors of survival were analyzed by a univariate analysis and further evaluated by multivariate Cox regression analysis to estimate the hazard ratio with 95% confidence interval (CI). All statistical analyses were performed with a two-sided significance value of 0.05.

Results
Patients and tumor characteristics
A total of 82 patients were eligible for analysis. Clinical baseline characteristics are detailed in Table 1. The mean age was 76.41 years, ranging from 70 to 87 years. Sixty-seven patients were male and 15 were female, with a sex ratio of 4.5:1.0; majority of patients (76.8%) had a good ECOG PS score (0–1). Approximately 36.8% patients had a severe dysphagia ≥2, and 30.5% had an initial weight loss >10% in 6 months. The median Charlson score was 2, and the most common comorbidity for this cohort was hypertension (n=37). Diabetic (30.5%) and peripheral vascular or cerebrovascular disease (12.2%) were ranked second and third in the data.

Detailed tumor characteristics before treatment are listed in Table 2. There were mainly T3–4 stage tumors (92.7%) and squamous cell carcinoma (n=74, 90.2%). Approximately 69.5% (n=57) patients were recorded with stage III–IV tumors with tumor locations as follows: upper-third (19/82, 23.1%), middle-third (37/82, 45.1%), and lower-third (13/82, 15.9%). A majority of tumors were more than 5 cm in length (72.0%).

Treatment compliance and tumor response to CCRT
All patients completed the first cycle of chemotherapy. Three patients refused the second cycle of chemotherapy, one patient developed refractory peritonitis during treatment and the other two got fever after occurrence of grade 4 leukopenia and grade 3 thrombocytopenia. These patients also gave up radiation. Eleven (13.4%) patients required dose reduction in the second cycle of chemotherapy for hematological toxicity, and the actual dose of PTX and CDDP was reduced to 105 and 25 mg/m2, respectively. Approximately 71 (86.6%) patients completed radiation, including four patients with radiation delay. A total of 66 (80.5%) patients finished CCRT
the following: 34 locoregional and local residual disease, 15 distant, and six in both sites.

Severe acute and late toxicities

The grade ≥3 acute toxicity profile of CCRT is listed in Table 3. Acute toxicity reactions were assessed in all 82 patients. The most common hematologic toxicity was leukopenia, with 15 (18.3%) patients and ten (12.2%) patients having grade 3 and 4 leukopenia, respectively. Most patients recovered by using G-CSF. Grade ≥3 thrombocytopenia was reported in three (3.6%) patients and six (7.3%) patients experienced grade ≥3 anemia. Twenty-eight patients got esophagitis during the treatment, including five (6.1%) patients and two (2.4%) patients with grade 3 and 4 esophagitis, respectively. Other main grade ≥3 nonhematologic toxicities included dysphagia (6.1%), nausea/vomiting (3.7%), mucositis (2.4%), and diarrhea (4.9%). One patient died of a fistula 0.97 months after the completion of treatment, and no cardiac toxicities or hypersensitivity reactions and alopecia related to PTX were reported. In terms of late toxicity, 12 (14.6%) patients got esophageal stenosis and six (7.3%) patients experienced radiation-related pneumonitis. Severe late radiation-associated toxicities affecting skin and heart were rare. In general, the regimen was well tolerated.

Survival and prognostic analysis

As shown in Figure 2, the median follow-up and OS of the overall population were 20.4 months (range, 0.97–67.4 months) and 26.9 months (95% CI, 23.2–30.6), respectively. The 2-year OS rate for stage I–II and III–IV was 76.0% and 38.6%, respectively.

Table 3 Grade ≥3 acute toxicities of concurrent chemoradiotherapy

| Factor | Grade 3 (%) | Grade 4 (%) | Grade 5 |
|--------|-------------|-------------|---------|
| Acute Hematologic toxicity | | | |
| Leukocytopenia | 15 (18.3) | 10 (12.2) | – |
| Anemia | 6 (7.3) | – | – |
| Thrombocytopenia | 2 (2.4) | 1 (1.2) | – |
| Nonhematologic toxicity | | | |
| Esophagitis | 5 (6.1) | 2 (2.4) | – |
| Dysphagia | 4 (4.9) | 1 (1.2) | – |
| Mucositis | 2 (2.4) | – | – |
| Diarrhea | 4 (4.9) | – | – |
| Nausea/vomiting | 3 (3.7) | – | – |
| Astriction | 1 (1.2) | – | – |
| Neurological/neuropathy | 1 (1.2) | – | – |
| Treatment-related death | – | – | 1 (1.2) |

Abbreviation: N, number of patients.
Overall survival and progression-free survival for the elderly esophageal cancer patients.

Figure 2

of the overall population was 18.2 months (95% CI, 11.583–24.817), and the 2-year PFS rate for stage I–II and III–IV was 64.0% and 21.2%, respectively. Univariate analyses were performed to assess the predictive capability of each variable (Table 4). The results suggested that several covariates were significantly associated with the OS: T stage ($P = 0.001$), N stage ($P = 0.000$), M stage ($P = 0.021$), clinical stage ($P = 0.000$), Charlson comorbidity score ($P = 0.002$), dysphagia ($P = 0.013$), clinical response ($P = 0.001$), ECOG PS ($P = 0.032$), and albumin ($P = 0.001$). The variables significantly associated with the PFS were T stage ($P = 0.000$), N stage ($P = 0.000$), clinical stage ($P = 0.000$), Charlson comorbidity score ($P = 0.015$), dysphagia ($P = 0.006$), clinical response ($P = 0.000$), and albumin ($P = 0.003$).

To identify independent prognostic factors, the factors that were found to be significant on univariate analysis were subjected to multivariate analysis. Multivariate analysis revealed that clinical stage ($P$-value was 0.042 and 0.024, respectively) was the independent factor affecting OS and PFS in elderly patients, and CR rate ($P = 0.054$) had statistical significance with PFS (Table 5).

**Discussion**

In this study, we presented a large cohort of elderly esophageal cancer patients treated with CCRT using PTX plus CDDP with curative intent. Our results showed that the median OS and PFS time were 26.9 and 18.2 months, with the 2-year OS rate of 76.0% and 38.6% for stage I–II and III–IV, respectively. These survival results seemed comparable with RTOG 0113 trial and a series of contemporary randomized studies of patients from all age groups undergoing definitive chemoradiation. In RTOG 0113, 35 patients were enrolled for the treatment of induction chemotherapy followed by chemoradiotherapy with PTX and CDDP for localized esophageal cancer, and their results showed that the median survival time was 14.9 months and 1- and 2-year OS rates were 69% and 37%, respectively. In another Phase II prospective clinical trial which investigated the efficacy and the safety of a 3-week schedule of PTX plus CDDP combined with concurrent radiotherapy for esophageal squamous cell cancer, the results showed that the overall median survival time was 28.5 months, the PFS was 14.7 months, and 1- and 2-year survival rates were 75% and 54%, respectively. Both these trials enrolled relatively nonelder patients (median age was 66 and 58 years, respectively). In our report, all patients were aged 70 years or older, and patients aged ≥75 years accounted for more than a half of the overall population. Although two patients with T1 stage were enrolled in our analysis, almost 70% of our cohort were in stages III–IV, which was also comparable with Tang et al’s report mentioned earlier (72.3% for stage III–IV). In 2015, Servagi-Vernat et al also conducted a Phase II clinical trial to evaluate the efficacy of CCRT comprising a single platinum-based agent combined with radiotherapy in patients ≥75 years of age with esophageal cancer, and their results showed that the 3-year OS rate and 2-year disease-free survival rate were 22.2% and 38%, respectively. They concluded that elderly patients should not be excluded from CCRT and that the elderly might be able to tolerate the treatment with acceptable acute toxicities. They also suggested that the therapeutic ratio or locoregional control might be improved by increasing the radiotherapy dose or by testing new radiosensitizer agents.

In general, the toxicities of the combined therapy were tolerable in our study. The main grade ≥3 toxicity was leukopenia, in 15 (18.3%) and ten (12.2%) patients with grade 3 and 4 leukopenia, respectively. Most of these elderly patients were treated by using G-CSF, which was monitored weekly during the treatment course for acute toxicity. Compared with
**Table 4** Univariate analysis demonstrating factors associated with OS and PFS

| Factor                        | Cases (n) | OS P-value | HR (95% CI) | PFS P-value | HR (95% CI) |
|-------------------------------|-----------|------------|-------------|-------------|-------------|
| Age (years)                   |           | 0.383      | 0.864 (0.632–1.199) | 0.342 | 0.852 (0.611–1.186) |
| 70≤ age <75                   | 39        |            |             |             |             |
| 75≤ age <80                   | 21        |            |             |             |             |
| Age ≥80                       | 22        |            |             |             |             |
| Sex                           |           | 0.256      | 0.647 (0.305–1.372) | 0.243 | 0.639 (0.302–1.355) |
| Female                        | 15        |            |             |             |             |
| Male                          | 67        |            |             |             |             |
| ECOG PS                       |           | 0.032      | 2.072 (1.065–4.033) | 0.122 | 1.664 (0.873–3.174) |
| 0–1                           | 63        |            |             |             |             |
| 2                             | 19        |            |             |             |             |
| Weight loss                   |           | 0.671      | 1.136 (0.630–2.048) | 0.979 | 1.008 (0.562–1.808) |
| ≤10%                          | 57        |            |             |             |             |
| >10%                          | 25        |            |             |             |             |
| Charlson comorbidity score    |           | 0.002      | 2.685 (1.431–5.037) | 0.015 | 2.091 (1.153–3.791) |
| 0–1                           | 27        |            |             |             |             |
| ≥2                            | 55        |            |             |             |             |
| T stage                       |           | 0.001      | 2.196 (1.371–3.520) | 0.000 | 2.518 (1.549–4.091) |
| T1                            | 2         |            |             |             |             |
| T2                            | 4         |            |             |             |             |
| T3                            | 54        |            |             |             |             |
| T4                            | 22        |            |             |             |             |
| N stage                       |           | 0.000      | 3.733 (1.860–7.491) | 0.000 | 3.892 (1.937–7.818) |
| N0                            | 28        |            |             |             |             |
| N1                            | 54        |            |             |             |             |
| M stage                       |           | 0.021      | 2.823 (1.169–6.816) | 0.118 | 1.986 (0.841–4.692) |
| M0                            | 74        |            |             |             |             |
| M1                            | 8         |            |             |             |             |
| Clinical stage                |           | 0.000      | 9.138 (3.590–23.262) | 0.000 | 9.491 (3.747–24.044) |
| I–II                          | 25        |            |             |             |             |
| III–IV                        | 57        |            |             |             |             |
| Tumor location                |           | 0.985      | 0.997 (0.762–1.306) | 0.846 | 0.974 (0.745–1.272) |
| Upper-third                   | 19        |            |             |             |             |
| Middle-third                  | 37        |            |             |             |             |
| Lower-third                   | 13        |            |             |             |             |
| Multi + unknown               | 13        |            |             |             |             |
| Differentiation               |           | 0.520      | 1.134 (0.773–1.662) | 0.567 | 1.112 (0.774–1.598) |
| Well                          | 10        |            |             |             |             |
| Fairly                        | 20        |            |             |             |             |
| Poorly                        | 49        |            |             |             |             |
| Unknown                       | 3         |            |             |             |             |
| Tumor length (cm)             |           | 0.098      | 1.701 (0.907–3.189) | 0.104 | 1.681 (0.899–3.143) |
| <5                            | 23        |            |             |             |             |
| ≥5                            | 59        |            |             |             |             |
| Albumin (g/L)                 |           | 0.001      | 3.782 (1.675–8.539) | 0.003 | 3.448 (1.541–7.717) |
| ≥30                           | 75        |            |             |             |             |
| <30                           | 7         |            |             |             |             |
| Hemoglobin (g/L)              |           | 0.091      | 1.424 (0.945–2.148) | 0.279 | 1.256 (0.831–1.898) |
| ≥10                           | 55        |            |             |             |             |
| 8≤ Hb <10                     | 18        |            |             |             |             |
| <8                            | 9         |            |             |             |             |
| Dysphagia                     |           | 0.013      | 1.967 (1.156–3.348) | 0.006 | 2.107 (1.237–3.588) |
| 0–1                           | 52        |            |             |             |             |
| ≥2                            | 30        |            |             |             |             |
| Clinical response             |           | 0.001      | 3.305 (1.661–6.578) | 0.000 | 3.899 (1.958–7.762) |
| CR                            | 29        |            |             |             |             |
| Non-CR                        | 53        |            |             |             |             |

**Abbreviations:** n, number of patients; OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; Hb, hemoglobin.
Table 5 Multivariate analysis of prognostic factors for patients with elderly esophageal cancer

| Endpoint | Factor             | P-value | HR (95% CI) |
|----------|--------------------|---------|-------------|
| OS       | T stage            | 0.604   | 0.831 (0.414–1.671) |
|          | N stage            | 0.533   | 1.487 (0.427–5.175) |
|          | M stage            | 0.841   | 1.111 (0.396–3.114) |
|          | Clinical stage     | 0.042   | 4.981 (1.062–23.352) |
|          | Charlson comorbidity score | 0.089 | 1.967 (0.903–4.285) |
| PFS      | Dysphagia          | 0.573   | 1.203 (0.634–2.282) |
|          | Clinical response  | 0.137   | 1.756 (0.836–3.688) |
|          | ECOG PS            | 0.286   | 1.510 (0.708–3.218) |
|          | Albumin            | 0.373   | 1.773 (0.504–6.241) |
|          | T stage            | 0.660   | 0.862 (0.445–1.670) |
|          | N stage            | 0.755   | 1.213 (0.362–4.066) |
|          | Clinical stage     | 0.024   | 5.988 (1.267–28.299) |
|          | Charlson comorbidity score | 0.073 | 1.932 (0.940–3.972) |
|          | Dysphagia          | 0.345   | 1.332 (0.735–2.415) |
|          | Clinical response  | 0.054   | 2.071 (0.986–3.905) |
|          | Albumin            | 0.746   | 1.213 (0.377–3.905) |

Abbreviations: OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status.

Table 5 shows the multivariate analysis of prognostic factors for patients with elderly esophageal cancer. The TP arm of RTOG 0113 trial in which the radiation dose was 50.4 Gy/28 Fx,20 the grade 3 and 4 adverse reactions of blood/bone marrow occurred in 40% (14/35) and 28.6% (10/35) of the cases, respectively; and the treatment-related death was 6%. Traditionally, elderly patients were considered to have less reserve of body function when compared with young patients, and our results indicated that with proper application of G-CSF, elderly patients could also undergo definitive treatment course without having a severe hematologic toxicity. The rate of severe esophagitis in our study was high compared with the results of Tang et al.12 Twenty-eight (34.1%) patients in our study got esophagitis, including five (6.1%) and two (2.4%) patients with grade 3 and 4, respectively; while in their report, only two patients suffered from grade 3 esophagitis and none had grade 4 esophageal dysfunction. Possible factors causing the high rate in our study are as follows: 1) a different radiation delivery schedule was used in their trial, 21% patients were given with a combination of conventional fractionation of 1.8 Gy/Fx and late-course accelerated hyperfractionated (LCAF) in a second course; 2) 72% patients in our analysis had ≥5 cm tumor, and tumor length has been confirmed as a significant prognostic factor for esophagitis in chest irradiation;25,26 3) total radiation dose in this study was 60 Gy as planned, and 86.6% elderly patients completed the radiation course. In 2007, we also did a Phase II clinical trial in our cancer center to investigate the toxicity of TP regime with 60 Gy/30 Fx radiotherapy for nonelderly esophageal cancer patients and showed comparable toxicities with this cohort. Nowadays, CCRT with 50.4 Gy is the standard treatment regimen for locally advanced esophageal cancer based on the results of RTOG 9405;4 this trial was designed to investigate whether high-dose irradiation in the setting of CCRT could achieve better survival results and local/regional control than 50.4 Gy CCRT. The results showed that higher radiation dose did not increase survival or local/regional control, and a higher treatment-related mortality rate was observed in the high-dose arm. But, interpretations about the results of RTOG 9405 trial were different; although, more treatment-related deaths in the 9405 trial occurred in the high-dose arm than in the 50.4 Gy arm (11 vs 2), seven of these eleven treatment-related deaths occurred before the dose of 50.4 Gy for unclear reasons. Therefore, more deaths were not as a result of high-dose radiation therapy, and our results also showed that only one patient suffered from treatment-related death (esophageal fistula). In the present study, we also confirmed that clinical stage was a strong prognostic factor in elderly patients, as shown in Table 5. A clinical response rate of CR had an approximately statistical significance with PFS; these findings were consistent with the results conducted by Tougeron et al.16 Their analysis revealed that factors of clinical CR, radiation dose, and Charlson score were independent prognostic factors with survival.

In conclusion, elderly patients (70 years or older) could benefit from definitive CCRT containing PTX, but attention should be paid to the relatively high incidence of toxicities. Further prospective studies in large cohorts of elderly esophageal cancer patients are highly warranted to confirm the findings in our report.

Acknowledgment
There was no funding support for this study. We thank Ruifei Xie for his help with translation and proofreading.

Disclosure
Tao Song and Xuebang Zhang are listed as co first authors. The authors report no conflicts of interest in this work.

References
1. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos. 2012. CA Cancer J Clin. 2012;62(5):283–298.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
3. Nallapareddy S, Wilding GE, Yang G, Iyer R, Javle M. Chemoradiation is a tolerable therapy for older adults with esophageal cancer. Anticancer Res. 2005;25(4):3055–3060.
4. Chino O, Makuuchi H, Machimura T, et al. Treatment of esophageal cancer in patients over 80 years old. Surg Today. 1997;27(1):9–16.
11. Ilson DH. New developments in the treatment of esophageal cancer. Curr Oncol Rep. 2002;4(3):213–221.

12. Tang HR, Ma HF, An SM, et al. A phase II study of concurrent chemoradiotherapy with paclitaxel and cisplatin for inoperable esophageal squamous cell carcinoma. Am J Clin Oncol. Epub April 11, 2014.

13. Zhang P, Xie CY, Wu SX. Concurrent chemoradiation with paclitaxel and platinum for locally advanced esophageal cancer. Zhonghua Zhong Liu Za Zhi. 2007;29(10):773–777. Chinese.

14. Takeuchi S, Ohtsu A, Doi T, et al. A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer. Am J Clin Oncol. 2007;30(6):607–611.

15. Feng JF, Huang Y, Chen L, Zhao Q. Prognostic analysis of esophageal cancer in elderly patients: metastatic lymph node ratio versus 2010 AJCC classification by lymph nodes. World J Surg Oncol. 2013;11:162.

16. Tougeron D, Di Fiore F, Thuereau S, et al. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer. 2008;99(10):1586–1592.

17. Atkinson M. Diseases of the alimentary system. Dysphagia. Br Med J. 1977;1(6053):91–93.

18. Charlson ME, Sax FL, MacKenzie CR, Braham RL, Fields SD, Douglas RG Jr. Morbidity during hospitalization: can we predict it? J Chronic Dis. 1987;40(7):705–712.

19. Li G, Hu W, Wang J, et al. Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2010;78(5):1407–1412.

20. Ajani JA, Winter K, Komaki R, et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol. 2008;26(28):4551–4556.

21. Zhao T, Chen H, Zhang T. Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. Med Oncol. 2012;29(5):3017–3023.

22. Nishimura Y, Mitsumori M, Hiraoka M, et al. A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021). Radither Oncol. 2009;92(2):260–265.

23. Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX and fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15(3):305–314.

24. Servaggi-Vernat S, Crehange G, Roulet B, et al. Phase II study of a platinum-based adapted chemotherapy regimen combined with radiotherapy in patients 75 years and older with esophageal cancer. Drugs Aging. 2015;32(6):487–493.

25. Gu T, Hua HX, Fu ZZ, et al. Multi-factor analysis of radiation-induced esophagitis in three-dimensional conformal radiotherapy for non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2011;33(11):868–871. Chinese.

26. Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer. 2002;95(7):1434–1443.